Evidence map›Paper›PMID 30255209›Full record

ArticlePharmaceutical research2018

Fragmentation of a Monoclonal Antibody by Peroxotungstate.

Hasitha Rathnayaka, Olivier Mozziconacci, Alavattam Sreedhara, Christian Schöneich

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hasitha RathnayakaDepartment of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Ave, Lawrence, Kansas, 66047, USA.
Olivier MozziconacciDepartment of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Ave, Lawrence, Kansas, 66047, USA.
Alavattam SreedharaLate Stage Pharmaceutical Development, Genentech Inc., S. San Francisco, California, 94080, USA.
Christian SchöneichDepartment of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Ave, Lawrence, Kansas, 66047, USA. schoneic@ku.edu.ORCID http://orcid.org/0000-0001-5082-8672

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTungsten and tungsten oxide leachates found in glass pre-filled syringes were identified to initiate protein precipitation and aggregation. Here, we tested the possibility of tungsten and tungsten oxide to induce the chemical degradation of proteins via reaction with hydrogen peroxide, a possible impurity present in protein formulations, to yield peroxotungstate.

methodsA monoclonal antibody (mAb) was incubated with various concentrations of peroxotungstate and the reaction mixtures analyzed by SDS-PAGE and mass spectrometry.

resultsExposure of a mAb to 1.07-1070 ppm peroxotungstate (based on tungsten content) at temperatures of 4°C and 22°C (pH 5-7) induced protein fragmentation. The extent of fragmentation increased with higher temperatures, lower pH and higher peroxotungstate concentrations. The mAb fragments were identified to contain different combinations of heavy chains (H) and light chains (L). Analogous mAb fragments were generated when the protein was exposed to H

conclusionFragmentation of the mAb by peroxotungstate is proposed to occur through inter-chain disulfide bond oxidation to form thiosulfinate (CyS(═O)SCy) and thiosulfonate [CyS(═O)

Indexed as

Antibodies, MonoclonalDisulfidesHumansHydrogen-Ion ConcentrationHydrogen PeroxideImmunoglobulin GInsulinOxidation-ReductionOxidesProteolysisTemperatureTungstenAntibodies, MonoclonalDisulfidesHydrogen PeroxideImmunoglobulin GInsulinOxidesTungstentungsten oxideFragmentationmonoclonal antibodyoxidationpre-filled syringestungsten

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.